{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088576","form_type":"8-K","ticker":null,"cik":"0001178879","company_name":"AMICUS THERAPEUTICS, INC.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.324105+00:00","generated_at":"2026-06-12T00:49:43.900987+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amicus Q2 rev $94.5M (+17% YoY); raises Galafold guidance to 14-18% growth; CFO Quimi to retire","bullets":["Q2 2023 total revenue $94.5M (+17% YoY at CER); net loss $43.2M ($0.15/sh), improved from $62.2M loss YoY.","Full-year Galafold revenue growth guidance raised to 14-18% at CER; non-GAAP operating expense guidance cut to $330M-$350M.","Company on track for non-GAAP profitability in H2 2023; expects U.S. and U.K. approvals of AT-GAA (Pombiliti+Opfolda) in Q3 2023.","CEO Quimi to retire; CFO role search underway with identified candidates; she will stay until successor appointed.","European launch of Pombiliti+Opfolda initiated in Germany; reimbursement discussions in additional EU countries ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088576","json":"https://secwatch.observer/filing/0001104659-23-088576.json","markdown":"https://secwatch.observer/filing/0001104659-23-088576.md","text":"https://secwatch.observer/filing/0001104659-23-088576.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178879/000110465923088576/0001104659-23-088576-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178879/000110465923088576/tm2323120d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T00:49:43.900987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26a1674281","claim":"Daphne Quimi departed as Chief Financial Officer at AMICUS THERAPEUTICS, INC..","evidence_excerpt":"The Company announced today that Daphne Quimi, the Company’s Chief Financial Officer, notified the Company on August 3, 2023 that she intends to retire before the end of 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178879/000110465923088576/0001104659-23-088576-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"intends to retire"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}